BioXcel Therapeutics Inc (BTAI)vsUnited Therapeutics Corporation (UTHR)
BTAI
BioXcel Therapeutics Inc
$0.07
-37.11%
HEALTHCARE · Cap: $5.10M
UTHR
United Therapeutics Corporation
$475.45
+0.69%
HEALTHCARE · Cap: $21.22B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 425035% more annual revenue ($3.15B vs $742,000). UTHR leads profitability with a 41.6% profit margin vs 0.0%. UTHR earns a higher WallStSmart Score of 61/100 (C+).
BTAI
Avoid27
out of 100
Grade: F
UTHR
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+27.7%
Fair Value
$2.24
Current Price
$0.07
$2.17 discount
Margin of Safety
+0.8%
Fair Value
$479.67
Current Price
$475.45
$4.22 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 51.7% year-over-year
Conservative balance sheet, low leverage
Keeps 42 of every $100 in revenue as profit
Strong operational efficiency at 42.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Attractively priced relative to earnings
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : BTAI
The strongest argument for BTAI centers on Revenue Growth, Debt/Equity. Revenue growth of 51.7% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.
Bear Case : BTAI
The primary concerns for BTAI are EPS Growth, Market Cap, Profit Margin.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
BTAI profiles as a hypergrowth stock while UTHR is a declining play — different risk/reward profiles.
UTHR carries more volatility with a beta of 0.56 — expect wider price swings.
BTAI is growing revenue faster at 51.7% — sustainability is the question.
UTHR generates stronger free cash flow (206M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (61/100 vs 27/100), backed by strong 41.6% margins. BTAI offers better value entry with a 27.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BioXcel Therapeutics Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
BioXcel Therapeutics, Inc., a clinical-phase biopharmaceutical company, focuses on the development of artificial intelligence-based drugs in the fields of neuroscience and immuno-oncology in the United States. The company is headquartered in New Haven, Connecticut.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?